Breakthrough

Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026…

You didn’t launch your startup to feel like a shell of yourself. However, somewhere between the endless pitching, tight cash flow and back-to-back 14-hour days, your spark started fading. You’re…